CC16 as an Inflammatory Biomarker in Induced Sputum Reflects Chronic Obstructive Pulmonary Disease (COPD) Severity

References

• Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99. doi:10.2147/copd.S27480
   PubMed Web of Science ®Google Scholar
• Global Initiative for chronic obstructinve pulmonary disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report); 2022.
   Google Scholar
• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Liu X, Du C, Hu F, et al. Management of acute exacerbation of chronic obstructive pulmonary disease under a tiered medical system in China. Ther Adv Respir Dis. 2022;16:17534666221075499. doi:10.1177/17534666221075499
   Google Scholar
• Mao R, Liu Z, Zhao Y, et al. Stable Chronic Obstructive Pulmonary Disease (COPD) management under a tiered medical system in China. Int J Chron Obstruct Pulmon Dis. 2022;17:181–194. doi:10.2147/COPD.S333274
   PubMed Web of Science ®Google Scholar
• Odeyemi YE, Lewis O, Ngwa J, et al. Does low FEV1 in addition to fixed ratio and/or lower limit of normal of FEV1/FVC improve prediction of mortality in COPD? The NHANES-III-linked-mortality Cohort. J Natl Med Assoc. 2019;111(1):94–100. doi:10.1016/j.jnma.2018.06.006
   PubMed Web of Science ®Google Scholar
• Moon JY, Leitao Filho FS, Shahangian K, Takiguchi H, Sin DD. Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD). Expert Rev Proteomics. 2018;15(11):923–935. doi:10.1080/14789450.2018.1539670
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3341–3348. doi:10.2147/copd.S176122
   PubMed Web of Science ®Google Scholar
• Proboszcz M, Mycroft K, Paplinska-Goryca M, et al. Relationship between blood and induced sputum eosinophils, bronchial hyperresponsiveness and reversibility of airway obstruction in mild-to-moderate chronic obstructive pulmonary disease. Copd. 2019;16(5–6):354–361. doi:10.1080/15412555.2019.1675150
   PubMedGoogle Scholar
• Paplińska-Goryca M, Nejman-Gryz P, Górska K, et al. Expression of inflammatory mediators in induced sputum: comparative study in asthma and COPD. Clinical Research Involving Pulmonary Disorders. Springer; 2016:101–112.
   Google Scholar
• Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax. 2008;63(12):1058–1063. doi:10.1136/thx.2008.102574
   PubMed Web of Science ®Google Scholar
• Hao W, Li M, Zhang C, Zhang Y, Wang P. Inflammatory mediators in exhaled breath condensate and peripheral blood of healthy donors and stable COPD patients. Immunopharmacol Immunotoxicol. 2019;41(2):224–230. doi:10.1080/08923973.2019.1609496
   PubMed Web of Science ®Google Scholar
• Toda A, Yokomizo T, Shimizu T. Leukotriene B4 receptors. Prostaglandins Other Lipid Mediat. 2002;68–69:575–585. doi:10.1016/s0090-6980(02)00056-4
   PubMed Web of Science ®Google Scholar
• Wang N, He X, Zhao J, et al. Structural basis of leukotriene B4 receptor 1 activation. Nat Commun. 2022;13(1):1156. doi:10.1038/s41467-022-28820-9
   PubMedGoogle Scholar
• Liang M, Lv J, Jiang Z, et al. Promotion of myofibroblast differentiation and tissue fibrosis by the leukotriene B(4) -leukotriene B(4) receptor axis in systemic sclerosis. Arthritis Rheumatol. 2020;72(6):1013–1025. doi:10.1002/art.41192
   PubMedGoogle Scholar
• Pasquini S, Contri C, Borea PA, Vincenzi F, Varani K. Adenosine and inflammation: here, there and everywhere. Int J Mol Sci. 2021;22(14):7685. doi:10.3390/ijms22147685
   PubMed Web of Science ®Google Scholar
• Hunt BG, Fox LH, Davis JC, et al. An introduction and overview of RON receptor tyrosine kinase signaling. Genes. 2023;14(2):517. doi:10.3390/genes14020517
   PubMedGoogle Scholar
• Paudel S, Ghimire L, Jin L, Jeansonne D, Jeyaseelan S. Regulation of emergency granulopoiesis during infection. Front Immunol. 2022;13:961601. doi:10.3389/fimmu.2022.961601
   PubMedGoogle Scholar
• Langer JA, Cutrone EC, Kotenko S. The class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev. 2004;15(1):33–48. doi:10.1016/j.cytogfr.2003.10.001
   PubMedGoogle Scholar
• Abolfathi H, Arabi M, Sheikhpour M. A literature review of microRNA and gene signaling pathways involved in the apoptosis pathway of lung cancer. Respir Res. 2023;24(1):55. doi:10.1186/s12931-023-02366-w
   PubMedGoogle Scholar
• Faramin Lashkarian M, Hashemipour N, Niaraki N, et al. MicroRNA-122 in human cancers: from mechanistic to clinical perspectives. Cancer Cell Int. 2023;23(1):29. doi:10.1186/s12935-023-02868-z
   PubMedGoogle Scholar
• Tomankova T, Petrek M, Kriegova E. Involvement of microRNAs in physiological and pathological processes in the lung. Respir Res. 2010;11(1):159. doi:10.1186/1465-9921-11-159
   PubMedGoogle Scholar
• Kara M, Kirkil G, Kalemci S. Differential expression of microRNAs in chronic obstructive pulmonary disease. Adv Clin Exp Med. 2016;25(1):21–26. doi:10.17219/acem/28343
   PubMed Web of Science ®Google Scholar
• Rosenberg SR, Kalhan R. Biomarkers in chronic obstructive pulmonary disease. Transl Res. 2012;159(4):228–237. doi:10.1016/j.trsl.2012.01.019
   PubMed Web of Science ®Google Scholar
• Tsikrika S, Dimakou K, Papaioannou AI, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine. 2017;99:281–286. doi:10.1016/j.cyto.2017.08.005
   PubMed Web of Science ®Google Scholar
• Liu X, Cui B, Wang Q, et al. Biomarkers for respiratory diseases: present applications and future discoveries. Clin Transl Discovery. 2021;1(1):e11. doi:10.1002/ctd2.11
   Google Scholar
• Zhu T, Li S, Wang J, et al. Induced sputum metabolomic profiles and oxidative stress are associated with chronic obstructive pulmonary disease (COPD) severity: potential use for predictive, preventive, and personalized medicine. EPMA J. 2020;11(4):645–659. doi:10.1007/s13167-020-00227-w
   PubMed Web of Science ®Google Scholar
• Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54–61. doi:10.1111/j.1440-1843.2006.00784.x
   PubMed Web of Science ®Google Scholar
• Zsoka W, Ildiko H. Induced sputum analysis: step by step educational aims. Breathe. 2013;9:301–306. doi:10.1183/20734735.042912
   Google Scholar
• Higham A, Cadden P, Southworth T, et al. Leukotriene B4 levels in sputum from asthma patients. ERJ Open Res. 2016;2(4):00088–2015. doi:10.1183/23120541.00088-2015
   PubMedGoogle Scholar
• Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88. doi:10.1164/rccm.201908-1590ST
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Soma T, Uchida Y, et al. Treatment resistance in severe asthma patients with a combination of high fraction of exhaled nitric oxide and low blood eosinophil counts. Front Pharmacol. 2022;13:836635. doi:10.3389/fphar.2022.836635
   PubMedGoogle Scholar
• Paggiaro PL, Chanez P, Holz O, et al. Sputum induction. Eur Respir J Suppl. 2002;37:3s–8s. doi:10.1183/09031936.02.00000302
   PubMedGoogle Scholar
• Yin G, Wu X, Wu Y, et al. Evaluating carbon content in airway macrophages as a biomarker of personal exposure to fine particulate matter and its acute respiratory effects. Chemosphere. 2021;283:131179. doi:10.1016/j.chemosphere.2021.131179
   PubMedGoogle Scholar
• Sun C-X, Young HW, Molina JG, et al. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest. 2005;115(1):35–43. doi:10.1172/jci22656
   PubMed Web of Science ®Google Scholar
• Dahl R, Titlestad I, Lindqvist A, et al. Effects of an oral MMP-9 and −12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. Pulm Pharmacol Ther. 2012;25(2):169–177. doi:10.1016/j.pupt.2011.12.011
   PubMed Web of Science ®Google Scholar
• Braido F, Riccio AM, Guerra L, et al. Clara cell 16 protein in COPD sputum: a marker of small airways damage? Respir Med. 2007;101(10):2119–2124. doi:10.1016/j.rmed.2007.05.023
   PubMed Web of Science ®Google Scholar
• Bi J, Min Z, Yuan H, et al. PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma. Clin Transl Med. 2020;9(1):22. doi:10.1186/s40169-020-0262-5
   PubMedGoogle Scholar
• Qaisar R, Karim A, Muhammad T. Circulating biomarkers of handgrip strength and lung function in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020;15:311–321. doi:10.2147/COPD.S225765
   PubMed Web of Science ®Google Scholar
• Rong B, Fu T, Gao W, et al. Reduced serum concentration of CC16 is associated with severity of chronic obstructive pulmonary disease and contributes to the diagnosis and assessment of the disease. Int J Chron Obstruct Pulmon Dis. 2020;15:461–470. doi:10.2147/COPD.S230323
   PubMed Web of Science ®Google Scholar
• Lam DC, Kwok HH, Yu WC, et al. CC16 levels correlate with cigarette smoke exposure in bronchial epithelial cells and with lung function decline in smokers. BMC Pulm Med. 2018;18(1):47. doi:10.1186/s12890-018-0607-7
   PubMedGoogle Scholar
• Guerra S, Halonen M, Vasquez MM, et al. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med. 2015;3(8):613–620. doi:10.1016/s2213-2600(15)00196-4
   PubMed Web of Science ®Google Scholar
• Laucho-Contreras ME, Polverino F, Tesfaigzi Y, et al. Club Cell Protein 16 (CC16) augmentation: a potential disease-modifying approach for Chronic Obstructive Pulmonary Disease (COPD). Expert Opin Ther Targets. 2016;20(7):869–883. doi:10.1517/14728222.2016.1139084
   PubMed Web of Science ®Google Scholar
• Knabe L, Fort A, Chanez P, Bourdin A. Club cells and CC16: another “smoking gun”? (With potential bullets against COPD). Eur Respir J. 2015;45(6):1519–1520. doi:10.1183/09031936.00010515
   PubMedGoogle Scholar
• Zhu L, Di PY, Wu R, Pinkerton KE, Chen Y. Repression of CC16 by cigarette smoke (CS) exposure. PLoS One. 2015;10(1):e0116159. doi:10.1371/journal.pone.0116159
   PubMedGoogle Scholar
• Pilette C, Godding V, Kiss R, et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(1):185–194. doi:10.1164/ajrccm.163.1.9912137
   PubMed Web of Science ®Google Scholar
• Mercer PF, Shute JK, Bhowmik A, et al. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005;6(1):151. doi:10.1186/1465-9921-6-151
   PubMedGoogle Scholar
• Chukowry PS, Spittle DA, Turner AM. Small airways disease, biomarkers and COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2021;16:351–365. doi:10.2147/COPD.S280157
   PubMed Web of Science ®Google Scholar
• Wells JM, Parker MM, Oster RA, et al. Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. JCI Insight. 2018;3(22). doi:10.1172/jci.insight.123614
   Web of Science ®Google Scholar
• Archambault AS, Poirier S, Lefebvre JS, et al. 20-Hydroxy- and 20-carboxy-leukotriene (LT) B(4) downregulate LTB(4) -mediated responses of human neutrophils and eosinophils. J Leukoc Biol. 2019;105(6):1131–1142. doi:10.1002/JLB.MA0718-306R
   PubMed Web of Science ®Google Scholar
• Laucho-Contreras ME, Polverino F, Gupta K, et al. Protective role for club cell secretory protein-16 (CC16) in the development of COPD. Eur Respir J. 2015;45(6):1544–1556. doi:10.1183/09031936.00134214
   PubMed Web of Science ®Google Scholar
• Zhai J, Insel M, Addison KJ, et al. Club cell secretory protein deficiency leads to altered lung function. Am J Respir Crit Care Med. 2019;199(3):302–312. doi:10.1164/rccm.201807-1345OC
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349. doi:10.2147/copd.S152291
   PubMed Web of Science ®Google Scholar
• David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. doi:10.1136/thoraxjnl-2020-215167
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019;74(7):1249–1256. doi:10.1111/all.13760
   PubMed Web of Science ®Google Scholar
• Almuntashiri S, Zhu Y, Han Y, et al. Club cell secreted protein CC16: potential applications in prognosis and therapy for pulmonary diseases. J Clin Med. 2020;9(12):4039. doi:10.3390/jcm9124039
   PubMed Web of Science ®Google Scholar
• Shijubo N, Itoh Y, Yamaguchi T, et al. Clara cell protein-positive epithelial cells are reduced in small airways of asthmatics. Am J Respir Crit Care Med. 1999;160(3):930–933. doi:10.1164/ajrccm.160.3.9803113
   PubMed Web of Science ®Google Scholar
• Chen LC, Zhang Z, Myers AC, Huang SK. Cutting edge: altered pulmonary eosinophilic inflammation in mice deficient for Clara cell secretory 10-kDa protein. J Immunol. 2001;167(6):3025–3028. doi:10.4049/jimmunol.167.6.3025
   PubMed Web of Science ®Google Scholar
• Johansson S, Andersson K, Wennergren G, Wenneras C, Rudin A. CC16 inhibits the migration of eosinophils towards the formyl peptide fMLF but not towards PGD2. Inflammation. 2009;32(2):65–69. doi:10.1007/s10753-008-9103-1
   PubMedGoogle Scholar
• Wang H, Long XB, Cao PP, et al. Clara cell 10-kD protein suppresses chitinase 3-like 1 expression associated with eosinophilic chronic rhinosinusitis. Am J Respir Crit Care Med. 2010;181(9):908–916. doi:10.1164/rccm.200904-0597OC
   PubMed Web of Science ®Google Scholar
• Li X, Guerra S, Ledford JG, et al. Low CC16 mRNA expression levels in bronchial epithelial cells are associated with asthma severity. Am J Respir Crit Care Med. 2022;206(12):1534–1545. doi:10.1164/rccm.202206-1230OC
   PubMedGoogle Scholar
• Jones PW. St. George’s respiratory questionnaire: MCID. Copd. 2005;2(1):75–79. doi:10.1081/copd-200050513
   PubMedGoogle Scholar
• Baldomero AK, Siddiqui M, Lo CY, et al. The relationship between oral health and COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2019;14:881–892. doi:10.2147/COPD.S194991
   PubMed Web of Science ®Google Scholar